Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioAlliance Pharma Announces Shareholders’ Meeting and Appointment of Independant Board Members

Published: Monday, July 01, 2013
Last Updated: Monday, July 01, 2013
Bookmark and Share
As a result of the shareholder’s meeting, Dr Russell Greig and Danièle Guyot-Caparros have been appointed as independent Board Members.

Dr Russell Greig holds a PhD in biochemistry from the University of Manchester. He held strategic positions at GlaxoSmithKline (GSK) for nearly three decades, notably as President of GSK Pharmaceuticals International from 2003 to 2008 and as a member of GSK Corporate Executive Team. Most recently, he served as President of SR One, GSK’s Corporate Venture Group. Since 2012, Russell has been a permanent guest member of the Board of Directors and has brought particular expertise to the Company in the area of Strategic Planning and Corporate Development.

Danièle Guyot-Caparros graduated from the Ecole Supérieure de Commerce of Nancy in finance and accounting. Following international missions in Audit, she joined Rhone Poulenc (now Sanofi) where she has held different positions with an increasing scope of responsibilities in finance on a European level and in business planning and performance monitoring on a worldwide level. Danièle has been working as a consultant specialized in life sciences and healthcare areas for 5 years.

“We are delighted to have Danièle and Russell joining our Board. Their appointment is in line with the Board’s expansion to international profiles and reinforces its skills in finance and strategy areas as well as its expertise in the pharmaceutical and biotechnology areas,” declared Judith Greciet, CEO of BioAlliance Pharma.

“I would like to join Judith in welcoming Danièle and Russell and warmly thank both departing members of the Board of Directors, Catherine and Michel, who brought their great professional experience to the Company these past few years. With its various backgrounds and skills, the new Board will actively pursue its role in defining and implementing the Company’s strategy and supporting its management team,” added Patrick Langlois, Chairman of the Board of Directors of BioAlliance Pharma.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!